Abstract：Objective To observe the clinical effect of bevacizumab combined with anlotinib in the treatment of non-small cell lung cancer（NSCLC）,and analyze its effect on immune status. Method A prospective randomized controlled study was conducted,selecting non-small cell lung cancer patients as the study subjects.The patients were divided into an observation group and a control group using a random number table method.The control group was treated with anlotinib,and the observation group was treated with anlotinib combined with bevacizumab.The clinical efficacy,T lymphocyte subsets（CD4+,CD3+,CD8+,CD4+/CD8+）,vascular endothelial growth factor（VEGF）level,KPS score,tumor marker level [serum carcinoembryonic antigen（CEA）,carbohydrate antigen 199（CA199）,CA125],survival time and adverse drug reactions were compared between the two groups. Results Before treatment,there was no statistical significant difference in various indicators between the two groups of patients（P>0.05）.After treatment,the disease control rate（DCR）,objective response rate（ORR）,CD4+,CD3+,CD4+/CD8+,and KPS scores of the observation group were significantly higher than those of the control group（P<0.05）.The levels of CD8+,VEGF,CEA,CA199,and CA125 in the observation group were lower than those in the control group（P<0.05）.Following up for 1 year,the median survival time of the observation group patients was 6 months,while the median survival time of the control group patients was 5 months.The total survival time of the observation group patients was significantly longer than that of the control group（lg rank=33.616,P<0.001）.There was no statistical significant difference in adverse reactions between the two groups（P>0.05）. Conclusion The combination of bevacizumab and anlotinib can improve the immune function and functional status of patients with non-small cell lung cancer,prolong the survival period,reduce the expression of tumor markers and VEGF,and has a good clinical effect.
丁妍华, 门帅, 张江霞, 张旭, 张善存, 刘璐, 吕宏伟, 肖正红. 贝伐珠单抗联合安罗替尼治疗非小细胞肺癌的临床疗效及对免疫状态的影响[J]. 哈尔滨医药, 2024, 44(1): 41-44.
Ding Yanhua, Men Shuai, Zhang Jiangxia, Zhang Xu, Zhang Shancun, Liu Lu, Lv Hongwei, Xiao Zhenghong. Clinical Efficacy of Bevacizumab Combined with Anlotinib in The Treatment of Non-small Cell Lung Cancer and Its Influence on Immune Status. journal1, 2024, 44(1): 41-44.
2024, Vol. 44 
